CoreWeave, Inc. Class A Common Stock
CRWV
$85.43
+5.00%
CoreWeave, Inc. Class A Common Stock operates as a modern cloud infrastructure company that provides NVIDIA GPUs and other essential AI hardware with optimized efficiency to handle the most demanding AI training and inference workloads. Its cloud platform supports the development and use of foundational large language models and the delivery of next-generation AI applications, positioning it as a specialized AI hyperscaler within the Technology sector's Software - Infrastructure industry. The company has attracted intense investor attention as a pure-play AI infrastructure provider, with a massive $104.2 billion backlog providing revenue visibility, but the narrative is increasingly dominated by concerns over soaring interest expenses, aggressive capital expenditure, and shareholder dilution from repeated fundraising efforts. Recent news highlights a tug-of-war between management's claims of demand exceeding supply and analyst worries about converting that backlog profitably amid high capital costs and competitive pressures.…
CRWV
CoreWeave, Inc. Class A Common Stock
$85.43
Related headlines
Investment Opinion: Should I buy CRWV Today?
The synthesized recommendation is Hold with a speculative bias. The core thesis is that CoreWeave's $104.2 billion backlog and 111.69% year-over-year revenue growth provide a compelling long-term AI infrastructure opportunity, but the company's 8.94x debt-to-equity ratio, -$10.62 billion TTM free cash flow, and -35.61% net margin make the risk-reward balanced rather than attractive at the current price. The analyst consensus rating of 'buy' with an average target of $144.44 implies 77.5% upside, but the wide target range of $39 to $317 and recent DA Davidson downgrade to Neutral highlight significant execution uncertainty.
Supporting evidence for a Hold includes the PS ratio of 6.07x, which is near the low end of its historical range since IPO, suggesting the stock is not expensive relative to its own history. Revenue growth of 111.69% year-over-year and positive EBITDA of $1.027 billion in Q1 2026 demonstrate underlying business momentum, and the EV/EBITDA multiple has compressed from 120.77x to 23.11x, making the valuation more reasonable on an EBITDA basis. However, the net margin of -35.61% and interest expense of $536 million exceeding operating income show that profitability remains elusive, and the company's reliance on $3.914 billion in net financing during Q1 2026 means dilution is an ongoing risk. The forward PE of -41.73x reflects expected losses, and the PEG ratio of -1.44 is non-informative due to negative earnings.
The biggest risks that could invalidate the thesis are a financing crisis if credit markets tighten, continued gross margin compression below 65%, and competitive pricing pressure from rivals like Nebius. This Hold would upgrade to Buy if gross margin stabilizes above 68% and interest expense growth moderates below 20% year-over-year, or if the stock falls below $65 with no deterioration in backlog conversion. It would downgrade to Sell if revenue growth decelerates below 50% year-over-year, if gross margin falls below 60%, or if the company announces another large equity raise at a discount to the current price. Relative to its history, the stock is undervalued on a PS basis, but relative to its risk profile and negative cash flows, it is fairly valued at best.
Sign up to view all
CRWV 12-Month Price Forecast
CoreWeave presents a high-risk, high-reward profile that balances a $104.2 billion backlog and triple-digit revenue growth against a highly leveraged balance sheet and deeply negative free cash flow. The stock's 32.98% one-year decline and -57.49% maximum drawdown have compressed the PS ratio to 6.07x, near historical lows, but this de-rating reflects legitimate concerns about profitability and dilution rather than a clear mispricing. The neutral stance reflects that while the long-term AI infrastructure opportunity is compelling, the near-term path to sustainable profitability is uncertain and dependent on factors largely outside management's control, including interest rates and credit market conditions. I would upgrade to bullish if gross margin stabilizes above 68% and interest expense growth decelerates below 20% year-over-year for two consecutive quarters, and downgrade to bearish if revenue growth falls below 50% or if the company announces another large equity raise at a discount.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CoreWeave, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $144.44 and implied upside of +69.1% versus the current price.
Average Target
$144.44
0 analysts
Implied Upside
+69.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$39 - $317
Analyst target range
CoreWeave is covered by 34 analysts, with a consensus recommendation of "buy" and a recommendation mean of 1.84 (where 1 is Strong Buy and 5 is Strong Sell), indicating a bullish tilt. The average target price is $144.44, which implies a substantial upside of approximately 77.5% from the current price of $81.36. The consensus leans bullish, but the wide dispersion of targets suggests significant disagreement among analysts. The target price range spans from a low of $39.00 to a high of $317.00, a spread of $278 or over 7x the current price, indicating high uncertainty. The high target of $317 assumes successful execution on the $104.2 billion backlog, margin expansion, and potentially multiple expansion as the company scales and achieves profitability. The low target of $39 prices in severe margin compression, competitive losses, and potential financing difficulties, reflecting the bear case of unsustainable debt and dilution. Recent institutional ratings show a mix of actions: DA Davidson downgraded from Buy to Neutral on 2026-05-18, while Cantor Fitzgerald maintained Overweight on multiple occasions, and Mizuho remained Neutral. The estimated EPS average of $14.12 for the forward year, with a range of $11.31 to $16.74, suggests analysts expect a swing to profitability, which contrasts with the current negative earnings and may be optimistic given the interest burden. The wide target spread and recent downgrade signal that while the long-term AI opportunity is compelling, near-term risks related to financing and profitability are significant.
Bulls vs Bears: CRWV Investment Factors
The bear case currently has stronger near-term evidence, driven by deteriorating profitability, a massive debt burden, and deeply negative free cash flow that requires continuous external financing. However, the bull case rests on a $104.2 billion backlog and 111.69% year-over-year revenue growth that could eventually drive profitability if capital costs stabilize and margins inflect. The single most important tension is whether CoreWeave can convert its backlog into profitable revenue before financing costs and dilution overwhelm shareholder value. If gross margin stabilizes above 65% and interest expense growth moderates, the stock could re-rate sharply toward analyst targets; if margins continue compressing and financing becomes more expensive, the equity could face a severe de-rating toward the bear-case target of $39. The stock's extreme volatility and wide analyst dispersion make position sizing critical, and the balance sheet leverage of 8.94x debt-to-equity leaves little room for error.
Bullish
- Massive $104.2B Backlog Provides Visibility: CoreWeave's contracted backlog of $104.2 billion represents roughly 12x trailing twelve-month revenue, providing exceptional multi-year revenue visibility. This backlog is underpinned by demand for NVIDIA GPU capacity that management claims exceeds available supply, suggesting revenue growth is contractually secured rather than speculative.
- Revenue Growth Still Triple-Digit YoY: Q1 2026 revenue of $2.078 billion grew 111.69% year-over-year from $981.6 million in Q1 2025, demonstrating that the AI infrastructure demand cycle remains robust. Sequential growth of approximately 32% from Q4 2025's $1.572 billion shows no sign of demand exhaustion despite the company's growing scale.
- Analyst Consensus Sees 77.5% Upside: With 34 analysts covering the stock, the consensus recommendation is 'buy' (mean 1.84) and the average target price of $144.44 implies 77.5% upside from the current $81.36. The high target of $317 suggests some analysts believe successful backlog conversion could drive a multi-bagger outcome.
- EBITDA Positive and Growing: Despite negative net income, Q1 2026 EBITDA was positive at $1.027 billion with an EBITDA margin of 49.4%, up from $438.7 million in Q1 2025. This shows the core business generates substantial cash before interest, taxes, depreciation, and amortization, and the EV/EBITDA multiple has compressed dramatically from 120.77x in Q3 2025 to 23.11x currently.
Bearish
- Interest Expense Exceeds Operating Income: Q1 2026 interest expense of $536 million exceeded operating income of -$144 million, and recent news reports interest expense hit $640 million last quarter, 2.4x the year-ago level. With debt-to-equity at 8.94 and a current ratio of 0.455, the company's ability to service this debt from operations is severely constrained.
- Deeply Negative Free Cash Flow and Heavy Dilution: TTM free cash flow is -$10.62 billion, driven by $7.695 billion in Q1 2026 capital expenditures alone, far exceeding operating cash flow of $2.984 billion. The company issued $1.985 billion in common stock and raised $3.914 billion in net financing during Q1 2026, diluting existing shareholders and increasing financial risk.
- Gross Margin Compression Accelerating: Gross margin has fallen from 72.97% in Q3 2025 to 67.61% in Q4 2025 and further to 65.54% in Q1 2026, indicating rising cost of revenue as the company scales. Net margin deteriorated to -35.61% in Q1 2026 from -28.74% in Q4 2025 and -8.07% in Q3 2025, showing losses are widening even as revenue grows.
- Extreme Price Volatility and Downtrend: The stock is down 32.98% over the past year and 31.02% over three months, trading at just 22.5% of its 52-week range with a maximum drawdown of -57.49%. Relative strength versus SPY is -47.99% over one year and -33.02% over three months, indicating persistent underperformance and negative momentum.
CRWV Technical Analysis
CoreWeave is in a sustained downtrend, with the stock trading at $81.36, down 32.98% over the past year and 31.02% over the past three months. The current price sits at approximately 22.5% of its 52-week range (low of $60.55 to high of $153.20), indicating the stock is much closer to its yearly low than its high, which typically signals either a value opportunity or a falling knife depending on fundamental catalysts. The maximum drawdown of -57.49% underscores the severity of the sell-off from peak levels, and the stock's position near the lower end of its range suggests persistent selling pressure and lack of near-term momentum. Recent momentum remains negative, with a 1-month decline of 10.47% and a 3-month decline of 31.02%, both significantly worse than the broader market as reflected in relative strength figures of -9.51% and -33.02% versus SPY over the same periods. The 6-month change of -0.14% is essentially flat, revealing a sharp deceleration from earlier gains and a divergence from the 1-year trend, which could signal a potential bottoming process or simply a pause before further weakness. The year-to-date change of +2.57% is marginally positive but masks extreme volatility, and the short ratio of 1.93 suggests moderate short interest that could fuel a squeeze if positive catalysts emerge. Key technical support is anchored at the 52-week low of $60.55, while resistance lies at the 52-week high of $153.20, with intermediate resistance likely around the $100-$110 zone where the stock has repeatedly failed. A breakdown below $60.55 would signal a new leg lower and likely trigger momentum-driven selling, while a breakout above $100 would be the first sign of a trend reversal. The stock's beta is not available in the provided data, but the extreme price swings and -57.49% max drawdown imply volatility well above the broader market, necessitating careful position sizing and risk management.
Beta
—
—
Max Drawdown
-57.5%
Largest decline past year
52-Week Range
$61-$153
Price range past year
Annual Return
-31.6%
Cumulative gain past year
| Period | CRWV Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +1.0% |
| 3m | -19.2% | +5.4% |
| 6m | -2.5% | +17.8% |
| 1y | -31.6% | +16.5% |
| ytd | +7.7% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRWV Fundamental Analysis
CoreWeave's revenue trajectory remains robust but is decelerating on a sequential basis, with Q1 2026 revenue of $2.078 billion representing 111.69% year-over-year growth from Q1 2025's $981.6 million. However, the sequential growth from Q4 2025's $1.572 billion to Q1 2026's $2.078 billion is approximately 32%, showing strong momentum but a slowdown from the prior quarter's pace. The multi-quarter trend reveals revenues of $981.6M, $1.213B, $1.365B, $1.572B, and $2.078B from Q1 2025 through Q1 2026, demonstrating consistent sequential growth but with the year-over-year growth rate likely compressing as the base scales. The massive $104.2 billion backlog provides exceptional revenue visibility, but the key question is whether the company can convert this backlog profitably given the capital-intensive nature of the business. Profitability remains elusive, with Q1 2026 net income of -$740 million and a net margin of -35.61%, significantly worse than the -28.74% net margin in Q4 2025 and the -8.07% in Q3 2025. Gross margin has been compressing, falling from 72.97% in Q3 2025 to 67.61% in Q4 2025 and further to 65.54% in Q1 2026, indicating rising cost of revenue as the company scales. The operating margin of -0.90% is negative but close to breakeven, while the interest expense of $536 million in Q1 2026 exceeds operating income, highlighting the heavy debt burden. The balance sheet is highly leveraged, with a debt-to-equity ratio of 8.94 and a current ratio of 0.455, indicating potential liquidity concerns. Free cash flow TTM is deeply negative at -$10.62 billion, driven by massive capital expenditures of $7.695 billion in Q1 2026 alone, far exceeding operating cash flow of $2.984 billion. The company is heavily dependent on external financing, having issued $1.985 billion in common stock and raised $3.914 billion in net financing during Q1 2026, which dilutes existing shareholders and increases financial risk. ROE is deeply negative at -34.99%, and the cash flow to debt ratio of 0.085 signals weak ability to service debt from operations.
Quarterly Revenue
$2.1B
2026-03
Revenue YoY Growth
+111.7%
YoY Comparison
Gross Margin
65.5%
Latest Quarter
Free Cash Flow
$-10.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRWV Overvalued?
Since CoreWeave's net income is negative (trailing EPS of -$0.037 and net income of -$740 million in Q1 2026), the PE ratio is not meaningful, and the PS ratio is the appropriate primary metric. The trailing PS ratio is 6.07x, while the forward PE is -41.73x, reflecting expected losses, and the EV/Sales is 11.88x, indicating a premium valuation relative to sales. The gap between the trailing PS of 6.07x and the forward PE of -41.73x suggests the market is pricing in significant future growth and eventual profitability, but the negative forward PE implies that profitability is not expected in the near term. Compared to the industry average, specific peer data is not provided, but the PS ratio of 6.07x and EV/Sales of 11.88x are elevated for a company with negative net margins and high capital intensity. The PB ratio of 9.34x is also high, reflecting the asset-heavy nature of the business and the premium investors are paying for the AI infrastructure theme. The PEG ratio of -1.44 is negative due to negative earnings, making it non-informative. Historically, the PS ratio has declined from 19.65x in Q1 2026 to 6.07x currently, and from 49.93x in Q3 2025, indicating significant multiple compression as the stock price fell and revenues grew. The current PS of 6.07x is near the low end of its historical range since IPO, which could suggest a value opportunity if growth remains robust, but it also reflects deteriorating profitability and balance sheet concerns. The EV/EBITDA of 23.11x is also elevated, though EBITDA is positive at $1.027 billion in Q1 2026, and the enterprise value multiple has compressed from 120.77x in Q3 2025 to 23.11x currently, showing a dramatic de-rating.
PE
-26.0x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.1x
Enterprise Value Multiple
Investment Risk Disclosure
CoreWeave's financial and operational risks are severe and quantifiable. The debt-to-equity ratio of 8.94 and current ratio of 0.455 indicate a highly leveraged balance sheet with potential liquidity concerns, while Q1 2026 interest expense of $536 million exceeded operating income of -$144 million. Free cash flow TTM is -$10.62 billion, driven by $7.695 billion in Q1 2026 capital expenditures alone, far exceeding operating cash flow of $2.984 billion, meaning the company depends on continuous external financing. Gross margin has compressed from 72.97% in Q3 2025 to 65.54% in Q1 2026, and net margin deteriorated to -35.61% in Q1 2026 from -8.07% in Q3 2025, showing that scaling is currently destroying rather than creating value. The cash flow to debt ratio of 0.085 signals a weak ability to service debt from operations, and ROE of -34.99% reflects the poor returns on the capital being deployed.
Market and competitive risks are equally significant. The stock trades at a premium valuation with a PS ratio of 6.07x and EV/Sales of 11.88x, despite negative net margins and high capital intensity, leaving it vulnerable to multiple compression if growth decelerates or profitability fails to materialize. The stock has underperformed SPY by 47.99% over one year and 33.02% over three months, and its maximum drawdown of -57.49% demonstrates extreme volatility that could intensify in a risk-off environment. Competitive pressures from other AI infrastructure providers like Nebius, which is aggressively expanding with customer prepayments funding over half its capex, could pressure pricing and margins. Regulatory and macro risks include potential changes to AI export controls, rising interest rates that increase the cost of CoreWeave's floating-rate debt, and sector rotation away from high-multiple AI infrastructure names if sentiment sours.
The worst-case scenario involves a chain of events where financing conditions tighten, forcing CoreWeave to raise capital at dilutive terms or higher interest rates, while simultaneously gross margins continue to compress and a major customer delays or cancels backlog commitments. This would trigger a liquidity crisis, accelerate shareholder dilution, and potentially lead to a restructuring or bankruptcy filing. In this scenario, the stock could fall to the 52-week low of $60.55, representing a 25.6% decline from the current price of $81.36, or even to the analyst low target of $39, a 52.1% decline. Given the maximum drawdown of -57.49% already experienced, a further 50%+ decline from current levels is a realistic tail risk if the financing environment deteriorates sharply.
FAQ
The most severe risk is financial: CoreWeave's debt-to-equity ratio of 8.94 and current ratio of 0.455 indicate a highly leveraged balance sheet, and Q1 2026 interest expense of $536 million exceeded operating income. A financing crisis or credit downgrade could force dilutive equity raises or asset sales, potentially driving the stock toward the 52-week low of $60.55 or the analyst low target of $39. The second major risk is operational: gross margin has compressed from 72.97% in Q3 2025 to 65.54% in Q1 2026, and net margin deteriorated to -35.61%, showing that scaling is currently destroying value. Third, competitive risk from rivals like Nebius, which is expanding aggressively with customer prepayments, could pressure pricing and backlog conversion. Fourth, macro risk: rising interest rates increase CoreWeave's cost of debt and could trigger sector rotation away from high-multiple AI infrastructure names, as evidenced by the stock's 47.99% underperformance versus SPY over one year.
The 12-month forecast has three scenarios: a base case with 50% probability targeting $95-$130, a bull case with 25% probability targeting $144-$200, and a bear case with 25% probability targeting $39-$60. The base case assumes revenue growth remains above 80% year-over-year but decelerates, gross margin stabilizes between 65-68%, and no major equity raise occurs at a significant discount. The bull case requires successful backlog conversion, gross margin above 68%, and a credible path to profitability, while the bear case involves a financing crisis, major customer delays, and gross margin falling below 60%. The most likely scenario is the base case, with the key assumption being that CoreWeave can manage its debt load without a dilutive equity raise and that AI infrastructure demand remains robust. The wide analyst target range of $39 to $317 reflects the high uncertainty in these outcomes.
CRWV is fairly valued to slightly undervalued relative to its own history but expensive relative to its current profitability. The trailing PS ratio of 6.07x is near the low end of its range since IPO, down from 49.93x in Q3 2025, and the EV/EBITDA of 23.11x has compressed dramatically from 120.77x. However, the forward PE of -41.73x reflects expected losses, and the PB ratio of 9.34x is high for a company with negative ROE of -34.99%. The market is paying a premium for future growth and eventual profitability, implying that investors expect CoreWeave to successfully convert its backlog into profitable revenue. If the company fails to achieve profitability within the next 2-3 years, the valuation could compress further toward the bear-case target of $39.
From a risk/reward perspective, CRWV is a speculative buy only for investors who can tolerate extreme volatility and have a multi-year horizon. The analyst consensus target of $144.44 implies 77.5% upside, and the $104.2 billion backlog provides exceptional revenue visibility, but the stock has fallen 32.98% over the past year and trades at just 22.5% of its 52-week range. The biggest downside risk is a financing crisis that could drive the stock to the analyst low target of $39, a 52.1% decline from the current $81.36. For risk-averse investors or those seeking income, CRWV is not a good buy given its -35.61% net margin and 8.94x debt-to-equity ratio. The stock is best suited for a small, speculative allocation within a diversified portfolio, with position sizing that accounts for the -57.49% maximum drawdown.
CRWV is suitable primarily for long-term investment with a minimum holding period of 3-5 years, given the company's early growth stage, negative earnings, and the multi-year nature of its $104.2 billion backlog conversion. The stock's extreme volatility, with a -57.49% maximum drawdown and 32.98% one-year decline, makes it unsuitable for short-term trading unless the trader has a high risk tolerance and active risk management. The company pays a negligible dividend with a yield of 0.09%, so there is no income component to support a shorter holding period. Earnings visibility is improving due to the backlog, but profitability remains elusive with a -35.61% net margin, meaning the investment thesis depends on long-term execution rather than near-term catalysts. A suggested minimum holding period of 3 years allows time for backlog conversion, margin stabilization, and potential profitability inflection.